Literature DB >> 8025235

The cytomegalovirus-antigenemia assay in the diagnosis of posttransplant cytomegalovirus infection.

B M Murray1, J Brentjens, D Amsterdam, J Myers, V Gray, I Pawlowski, K Schewegler, J P Singh, R C Venuto.   

Abstract

Cytomegalovirus (CMV) infection continues to be a major cause of morbidity and mortality in transplant recipients, yet prompt diagnosis remains a problem. A new assay has been developed that detects CMV antigens in peripheral blood leukocytes (CMV-AG). A retrospective analysis of the experience with this assay was performed, and its usefulness in the diagnosis of CMV infection in renal transplant recipients with unexplained fever was compared with that of conventional modalities (buffy coat culture, detection of circulating anti-CMV immunoglobulin M). The results suggest that the CMV-AG assay is a more rapid and sensitive test than existing modalities in the early diagnosis of CMV infection. When expressed quantitatively, it can discriminate between CMV infection and CMV disease, and it is useful in monitoring the course of infection and the response to therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8025235     DOI: 10.1681/ASN.V481615

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  3 in total

1.  EARLY DIAGNOSIS IN POST RENAL TRANSPLANT OPPORTUNISTIC INFECTIONS: A FRESH LOOK.

Authors:  G S Chopra; A S Narula; P S Reddy; J R Bhardwaj
Journal:  Med J Armed Forces India       Date:  2017-06-26

2.  Rapid cytomegalovirus pp65 antigenemia assay by direct erythrocyte lysis and immunofluorescence staining.

Authors:  S K Ho; C Y Lo; I K Cheng; T M Chan
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

3.  Predictive value of quantitative PCR-based viral burden analysis for eight human herpesviruses in pediatric solid organ transplant patients.

Authors:  X Bai; B B Rogers; P C Harkins; J Sommerauer; R Squires; K Rotondo; A Quan; D B Dawson; R H Scheuermann
Journal:  J Mol Diagn       Date:  2000-11       Impact factor: 5.568

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.